Director/PDMR Shareholding

RNS Number : 6579V

Proteome Sciences PLC

06 April 2023

 

6 April 2023

Proteome Sciences plc

("Proteome Sciences" or the "Company")

Director/PDMR Shareholding

The Company has received notification from Vulpes Investment Management Pte Ltd ("Vulpes") that on 4 and 5 April 2023 it purchased, respectively, 14,766 and 100,000 ordinary shares of 1p in the capital of the Company ("Ordinary Shares") at a price of 4p per Ordinary Share (the "Purchase"). Following the Purchase, Vulpes has a total direct and indirect interest in 67,589,772 Ordinary Shares, equivalent to 22.89% of Proteome Sciences' total issued share capital.

By virtue of Martin Diggle being a Director of both Vulpes and the Company, he now has an interest in 67,589,772 Ordinary Shares of the Company representing 22.89% of the issued share capital of the Company.

The below notification is made in accordance with the requirements of the Market Abuse (amendment) (EU Exit) Regulations 2019/310.

1.	Details of the person discharging managerial responsibilities/person closely associated
a)	Name:	Martin Diggle
	Reason for the notification
a)	Position/status:	Non-Executive Director
b)	Initial notification/Amendment:	Initial Notification
	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name:	Proteome Sciences Plc
b)	LEI:	213800Q62ICXANKU2986
	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument: Identification code:	Ordinary Shares of 1p nominal value GB0003104196
b)	Nature of the transaction:	Purchase of Ordinary Shares
c)	Price(s) and volume(s):	Price(s) Volume(s) 4.00p 14,766 4.00p 100,000
d)	Aggregated information: · Aggregated volume: · Price:	Single transaction as in 4 c) above Average Price Volume(s) 4.00p 114,766
e)	Date of the transaction:	4 and 5 April 2023
f)	Place of the transaction:	London Stock Exchange, AIM (XLON)

For further information please contact:

Proteome Sciences plc
Dr. Mariola Soehngen, Chief Executive Officer Dr. Ian Pike, Chief Scientific Officer	Tel: [phone]
Richard Dennis, Chief Commercial Officer Abdelghani Omari, Chief Financial Officer
Allenby Capital Limited (Nominated Adviser & Broker)
John Depasquale / Jeremy Porter	Tel: [phone]

About Proteome Sciences plc. ( www.proteomics.com )

Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant® and TMT®MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator™ provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.

 

END

 

 

DSHSSEFSMEDSEDL